VKTX · Viking Therapeutics, Inc.

Not today. VKTX is not on today's radar: no tight base just under a resistance that has been tested again and again.

Bulls: VK2735 is advancing into Phase 3 in both oral and subcutaneous formulations after strong earlier data, with a 2–4% share of the US obesity market implying $40B–$55B in cumulative VK2735 sales through 2045; bulls also flag ~$1B in cash earning 4% interest against a ~$24/share price versus analyst one-year estimates of $90/share. The company's secondary raise is framed as giving it negotiating power, with several pharma companies seen needing a VK2735 buyout even more than $NVO, and Q3 earnings due Wed Oct 28 after close viewed as a progress print rather than a revenue event. Near-term catalysts cited include amylin 3019 SAD data and a January bounce after heavy tax-loss selling.

Bears: The stock fell 5.5% to $24.40, closing at the low of its 20-day range ($24.36–$35.19), below the 50-day EMA ($30.42) and 200-day ($32.46), with daily RSI at 36 and ~$23.3 as the last support — no bounce call until it reclaims ~$31. Bears cite substantial cash burn, dilution and uncertain commercialization economics, note the stock was raised at $35 on the way down and is now sub-$25, and call it one of the biggest retail trap names. They also question why top biotech investors aren't buying in size at $24/share and argue the stock looks overvalued next to book value, while management is criticized as 12 years with zero partnered assets, headed solo.

Reading from Oct 28, 2026; each post classified by AI, weighted by engagement.

No recent news reading for VKTX. The News Sentiment API reads today's headlines on any US stock.

Open-market trades only, from SEC Form 4 filings — option exercises, tax withholding and grants are left out.

• Bought · Aubuchon Neil William$150K · Mar 10, 2026
• Sold · FOEHR MATTHEW W$562K · Jan 2, 2026
• Sold · Rowland Charles A Jr$2.1M · Oct 27, 2025

From the company's SEC filings (10-Q and 10-K).